Treated PPMS subjects had significantly increased percentages of CD4+CD25+, FOXP3+, and CTLA-4+ (p < 0.004) compared with untreated PPMS subjects (p < 0.01) (Table 3). This evidence concerns the gene FOXP3 and primary progressive multiple sclerosis.